# Single Dose Study of MK-2060 to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics in Older Japanese Participants on Dialysis (MK-2060-012)

> **NCT05769595** · PHASE1 · COMPLETED · sponsor: **Merck Sharp & Dohme LLC** · enrollment: 17 (actual)

## Conditions studied

- End-Stage Renal Disease (ESRD)
- End-Stage Kidney Disease (ESKD)
- Kidney Failure, Chronic

## Interventions

- **BIOLOGICAL:** MK-2060
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT05769595
- **Lead sponsor:** Merck Sharp & Dohme LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2023-06-14
- **Primary completion:** 2024-02-15
- **Final completion:** 2024-02-15
- **Target enrollment:** 17 (ACTUAL)
- **Last updated:** 2025-03-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05769595

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05769595, "Single Dose Study of MK-2060 to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics in Older Japanese Participants on Dialysis (MK-2060-012)". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05769595. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*